General Fundraising

EHE Research - Dr. Brian Rubin

Dr. Brian Rubin – a world-renowned pathologist and medical researcher who has made invaluable contributions to sarcoma diagnosis and treatment – provides hope for patients diagnosed with Epithelioid Hemangioendothelioma (EHE).

  • EHE is a rare and often deadly vascular sarcoma that primarily affects adolescents and young adults.
  • Dr. Rubin is a global leader in EHE research, he discovered the disease’s genetic underlying cause and, in 2013, became the first to grow and sustain an EHE cell line.
  • He is also a deeply respected friend to the EHE community: patients know him as not only a great scientist but also as a truly approachable and caring human being who’s always willing to consider cases and give critical advice.


Now, Dr. Rubin is testing and developing therapeutic interventions based on his research, and initiating the first rational-based clinical trial for EHE patients.

  • These are historic milestones that promise, for the first time since EHE was diagnosed in 1982, effective treatment and real hope for thousands of patients around the world.


To make the dream of effective EHE treatment come true, WE NEED YOUR HELP, NOW!

  • Scientific studies cost money – they are labor intensive and most of the scientific budget is for research technicians and post-doctoral research associates.
  • It costs $75,000 to $100,000 to pay the yearly salary and reagent costs for a single researcher.
  • Currently, The National Institutes of Health and the National Cancer Institute (NIH/NCI) do not fund any EHE or EHE-related projects. While Dr. Rubin is very hopeful that his lab will obtain long-term NIH/NCI funding for EHE research, for now, EHE patients, their families and their friends have stepped up to fill the funding gap.


Please join us! By making a donation today, you’ll make a very real difference in the lives of EHE patients and their families. Any contribution helps ensure that this important, life-saving work continues to move forward.


Dr. Brian Rubin – Career Highlights

  • Professor of Pathology and Vice-Chair of Research within the Robert J. Tomsich Pathology & Laboratory Medicine Institute within the Cleveland Clinic
  • World-renowned molecular pathologist and researcher with a successful track record and a focused interest in the diagnosis and treatment of sarcomas
  • Author of over 100 peer-reviewed journal articles and author of numerous reviews and book chapters on sarcomas
  • Co- authored the WHO Classification of Tumors of Bone and Soft Tissue Tumors (sarcomas) (2002 and 2012)
  • Played key roles in the identification of therapeutic targets in gastrointestinal stromal tumor (GIST) and dermatofibrosarcoma protuberans – resulting in FDA approval of imatinib mesylate - Gleevec as first line medical therapy in these diseases